Plaintiffs Renew Schering Off-Label Marketing Claims

Law360, New York (May 6, 2010, 6:22 PM EDT) -- A group of health and welfare funds, third-party payors and individual consumers have revamped their putative class action accusing Schering-Plough Corp. of illegally marketing its drugs Intron-A and Temodar for off-label uses.

The plaintiffs filed their 168-page amended consolidated class action complaint Wednesday in the U.S. District Court for the District of New Jersey, repleading their Racketeer Influenced and Corrupt Organizations Act claims after a judge rejected their theory of injury in July.

After conducting additional discovery, the plaintiffs added to their complaint descriptions of Schering...
To view the full article, register now.